Thursday, 15 October 2026European Markets

Pentagon signs AI deals with OpenAI and Google as Anthropic reverses course on defense work

The US Defense Department secured AI contracts with OpenAI and Google within days of Anthropic filing a lawsuit against the Pentagon, yet Anthropic CEO Dario Amodei has resumed contract negotiations. The rapid shift from public opposition to negotiation suggests competitive pressure is overriding earlier ethical stances as governments pursue multi-vendor AI strategies.

Pentagon signs AI deals with OpenAI and Google as Anthropic reverses course on defense work
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

OpenAI and Google finalized separate agreements with the Pentagon this week, with Google introducing AI agents to defense operations on March 10, 2026. The deals came just one day after Anthropic sued the Department of Defense on March 9.

Anthropic CEO Dario Amodei has now put a military contract "back on the table" through resumed negotiations with the Defense Department. The company stated it seeks to harness AI for national security protection, marking a reversal from its lawsuit position filed 72 hours earlier.

European defense ministries are watching this consolidation closely. The Pentagon's multi-vendor approach creates a competitive dynamic where AI companies risk market exclusion by maintaining ethical objections while rivals secure government access.

The timeline reveals how quickly positions shift under competitive pressure. Anthropic filed legal action against the Pentagon on a Monday. By Thursday, with OpenAI and Google already contracted, Anthropic had reopened talks.

For European governments developing AI procurement strategies, the pattern suggests exclusive partnerships with single vendors may be giving way to diversified supplier bases. This approach lets defense agencies avoid dependence on any single company while pressuring vendors to participate or lose strategic contracts.

The US defense AI market is accelerating vendor competition rather than consolidating around one provider. Companies that initially cited ethical concerns about military applications are reconsidering as competitors gain preferential access to government resources and data.

European defense procurement officers have historically favored vendor diversity to maintain strategic independence. The Pentagon's current approach validates this model, using contract distribution across multiple AI providers to prevent vendor lock-in while ensuring no company can afford to opt out.

The shift from Anthropic's public lawsuit to private negotiations within one business week indicates competitive pressure now outweighs earlier reservations about defense work among leading AI companies.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com